Genentech announces updated data from Venclexta® clinical trials

Chronic lymphocytic leukemia (CLL) is a common type of adult leukemia. In the United States, it is estimated that more than 20,000 new cases of CLL will be diagnosed in 2019. With an eye to cure CLL, biotechnology company Genentech, Inc. has recently announced updated data from two pivotal Phase 3 Venclexta® clinical trials (CLL14 and MURANO).

The studies highlight that Venclexta combination therapies as chemotherapy-free, fixed-duration option that achieved MRD (minimal residual disease)-negativity, in people with CLL. Reportedly, Phase 3 CLL14 study accessed the combination of Venclexta plus Gazyva® (obinutuzumab) in untreated CLL patients, who had co-existing medical conditions.

At a median follow-up of over three years, when all patients had been off therapy for more than 24 months, Venclexta plus Gazyva demonstrated high response rates, comprising MRD-negativity.

In an updated analysis of CLL14, the chemotherapy-free, fixed-duration of Venclexta plus Gazyva combination reduced the chances of disease worsening by 69% in comparison with Gazyva plus chlorambucil. Moreover, it attained remissions that were stable over time in patients with untreated CLL.

The Phase III MURANO trial meanwhile evaluated Venclexta plus Rituxan® (rituximab) combination in relapsed or refractory CLL. After a 4-year follow-up, the combination showed positive activity by lowering disease progression as compared to a standard of care therapy in previously treated CLL. 

According to Levi Garraway, M.D., Ph.D., CMO, and Head of Global Product Development, Roche, Venclexta with anti-CD20 monoclonal antibody-based regimens is continuously showing improved long terms results for people who are suffering from CLL. These updated analyses reinforced the sustained clinical benefits observed in patients with CLL, after completing chemotherapy-free, fixed duration treatment. 

Reliable reports cite that Venclexta is being developed by Genentech and AbbVie. It is jointly commercialized by both companies in the U.S. and commercialized by AbbVie abroad. Meanwhile, the data from Venclexta clinical development program will be presented in over 50 abstracts at 61st ASH (American Society of Hematology) annual meet. 

Source Credit - https://www.gene.com/media/press-releases/14829/2019-12-08/new-data-demonstrate-the-continued-clini